Camila Coelho, PhD MBA

@sinaiimmuno.bsky.social

Mount Sinai Scientists Identify Three Potent Human Antibodies Against Mpox, Paving the Way for New Protective Therapies

www.mountsinai.org/about/newsro...
@sinaiimmuno.bsky.social

Check our new paper here!
👇🏼

Three potent human antibodies against mpox pave way for new protective therapies A team from the Microbiology Department at the Icahn School of Medicine at Mount Sinai has discovered three powerful monoclonal antibodies from a person who had previously been infected with mpox (formerly known as monkeypox).

Three monoclonal antibodies targeting the mpox virus protein A35 have shown strong protection against severe disease in laboratory and animal models, indicating potential for new therapeutic approaches. doi.org/g9zg4h

Human monoclonal antibodies targeting A35 protect from death caused by monkeypox virus @cellcellpress.bsky.social @carolilucas.bsky.social @vivianasimonlab.bsky.social @mschotsaert.bsky.social
www.cell.com/cell/fulltex...

Speeding up vaccine design and antibody discovery using cryoEM and AI/ML Title:Speeding up vaccine design and antibody discovery using cryoEM and AI/ML Speaker: Andrew Ward, Scripps Research, United States     MODERATOR:  Camila Coelho, Icahn School of Medicine at Mou...

It starts in 10 minutes!
Link below👇
isv-online.org/event/isv-au...

Exciting data from @camilahcoelho.bsky.social lab! Congratulations to the team!

New paper from the Coelho lab with a modest contribution from us:

Join us next Wednesday as we hear from the great work from the Ward lab!

🙌 This work was a major collaboration with incredible colleagues across the US, and we’re grateful for Mount Sinai's support.
#Mpox #Antibodies #Immunology
[9/9]

💡 Translational highlight: In mpox patients, polyclonal antibodies targeting this same A35 groove were enriched and correlated with better outcomes (shorter symptoms, no hospitalization).
Vaccination with Jynneos or Dryvax did not induce these antibodies.
[8/9]

Structural studies revealed all these mAbs, despite very different binding loops, converge on the groove formed by the A35 dimer.
This region is highly conserved across orthopoxviruses and even the broader poxvirus family.
[7/9]

How do they work?
✔️ Direct viral neutralization
✔️ Fc functions (required for optimal protection)
[6/9]

Treatment worked at just ~5 mg/kg...that’s 10x lower than the antibody doses used during recent Ebola outbreaks.
Even at low concentrations, these mAbs were outstandingly potent.
[5/9]

✨ In collaboration with Ian Wilson, Bernie Moss, @carolilucas.bsky.social, @mschotsaert.bsky.social @vivianasimonlab.bsky.social, that’s exactly what we did!
We now have highly potent A35 human mAbs, in vitro and in vivo. They are protective both before and after mouse infection.
[4/9]

This led us to hypothesize: if we could map where strong anti-A35 antibodies bind (the epitope), we could uncover urgently needed therapeutics and reveal viral weak spots that vaccines could target.
[3/9]

💡 In 2023, our lab showed (PMID: 37475115) that people infected with mpox had unusually high antibody levels against A35, a surface protein of MPXV.
These antibodies neutralized the virus better than antibodies from people vaccinated with Jynneos or Dryvax.
[2/9]

Human monoclonal antibodies targeting A35 protect from death caused by mpox Three potent mAbs against the conserved MPXV A35 protein block viral spread, protect against lethal infection in mice, and align with protective antibody responses in convalescent humans, establishing...

🚨 New article! Our study "Human monoclonal antibodies protect against death caused by mpox" is now published:
👉 www.cell.com/cell/fulltex...
[1/9]

Join us next Wednesday as we hear from the great work from the Ward lab!

Such a great time at the #IUIS2025! Inspiring conferences by amazing scientists such as @belkaidlab.bsky.social @virusesimmunity.bsky.social @linterman.bsky.social. Also loved seeing rising stars like @camilahcoelho.bsky.social @marionbrunck.bsky.social. Thanks to James Allison for his lecture !! ❤️

Camila Coelho, PhD, MBA, Named Rising Star by Union of Immunological Societies

Congratulations to former LJI trainee Dr. Camila Coelho (now at the Icahn School of Medicine at Mount Sinai)! 🎉

Dr. Coelho has been named a "Rising Star" by Union of Immunological Societies — an award for early-stage researchers who are revolutionizing the field! bit.ly/4mGyF3H #health #medicine

Thank you Juan and so wonderful meeting you!

Fascinating talk by rising star @camilahcoelho.bsky.social - Latin America representing @iuis-online.bsky.social #IUIS2025

@cellpress.bsky.social @cp-cellreports.bsky.social @sinaiimmuno.bsky.social

Congrats to PhD student @vishalnrao.bsky.social, and to our Mount Sinai Microbiology friends @gogo-science.bsky.social , @vivianasimonlab.bsky.social, Florian Krammer. Finally, to our Harvard colleague @affinityborn.bsky.social and all the other scientists who worked to make this possible! [4/4]

🤔 Why is this important?
By understanding which mutations make antibodies more potent, we can design vaccines that “train” the immune system to produce stronger and more broadly protective antibodies, not only for COVID-19, but potentially for other diseases as well. [3/4]